- The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants
- The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University
- The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world
Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.